Inhibitory effects of glucocorticoids on rat eosinophil superoxide generation and chemotaxis

International Immunopharmacology

Volumn 3, Issue 6, 2003, Pages 845-852

  Sugimoto, Yukio ^a   Ogawa, Masami ^b   Tai, Nobuyuki ^a   Kamei, Chiaki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Research and Development Division   (Japan)

Author keywords

Beclomethasone dipropionate; Chemotaxis; Dexamethasone; Eosinophil; Mometasone furoate; Superoxide generation

Indexed keywords

BECLOMETASONE DIPROPIONATE; DEXAMETHASONE; GLUCOCORTICOID; LEUKOTRIENE B4; MOMETASONE FUROATE; PHORBOL 13 ACETATE 12 MYRISTATE; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR;

ALLERGIC DISEASE; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MIGRATION; CELL STIMULATION; CHEMOTAXIS; CONCENTRATION RESPONSE; DRUG SCREENING; EOSINOPHIL; IMMUNOMODULATION; IMMUNOSTIMULATION; MALE; MIGRATION INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0038054211     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00055-9     Document Type: Article

References (46)

1. Frigas E., Gleich G.J. The eosinophil and the pathophysiology of asthma. J. Allergy Clin. Immunol. 77:1986;527-537.
2. Leiferman K.M., Peters M.S., Gleich G.J. The eosinophil and cutaneous edema. J. Am. Acad. Dermatol. 15:1986;513-517.
3. Harlin S.L., Ansel D.G., Lane S.R., Myers J., Kephart G.M., Gleich G.J. A clinical and pathologic study of chronic sinusitis: the role of the eosinophil. J. Allergy Clin. Immunol. 81:1988;867-875.
4. Capron M., Tomassini M., Torpier G., Kusnierz J.-P., MacDonald S., Capron A. Selectivity of mediators released by eosinophils. Int. Arch. Allergy Immunol. 88:1989;54-58.
5. Boyce J.A. The pathobiology of eosinophilic inflammation. Allergy Asthma Proc. 18:1997;293-300.
6. Woschnagg C., Rak S., Venge P. Oxygen radical production by blood eosinophils is reduced during birch pollen season in allergic patients. Clin. Exp. Allergy. 26:1996;1064-1072.
7. Lumry W.R. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J. Allergy Clin. Immunol. 104:1999;150-158.
8. Mori A. Current understanding and problems of steroid-resistant asthma. Allergol. Intern. 49:2000;225-230.
9. Peterson A.P., Altman L.C., Hill J.S., Gosney K., Kadin M.E. Glucocorticoid receptors in normal human eosinophils: comparison with neutrophils. J. Allergy Clin. Immunol. 68:1981;212-217.
10. Nittoh T., Fujimori H., Kozumi Y., Ishihara K., Mue S., Ohuchi K. Effects of glucocorticoids on apoptosis of infiltrated eosinophils and neutrophils in rats. Eur. J. Pharmacol. 354:1998;73-81.
11. Lisle H., Howat D., Hughes B. IL-5-induced eosinophilia in the rat pleural cavity: the effect of dexamethasone and indomethacin. Br. J. Pharmacol. 108:1993;230P.
12. Hughes B., Howat D., Lisle H., Holbrook M., James T., Gozzard N.et al. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br. J. Pharmacol. 118:1996;1183-1191.
13. Namovic M.T., Walsh R.E., Goodfellow C., Harris R.R., Carter G.W., Bell R.L. Pharmacological modulation of eosinophil influx into the lungs of Brown Norway rats. Eur. J. Phamacol. 315:1996;81-88.
14. Meltzer E.O., Jalowayski A.A., Orgel H.A., Harris A.G. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J. Allergy Clin. Immunol. 102:1998;39-49.
15. Wilson A.M., Sims E.J., McFarlane L.C., Lipworth B.J. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J. Allergy Clin. Immunol. 102:1998;598-604.
16. Kamei C., Sugimoto Y., Kakinoki H., Izumo T., Ichiki C. Effect of mometasone furoate on experimental allergic rhinitis in rats. Jpn. Pharmacol. Ther. 23:1995;109-112.
17. Sugimoto Y., Ishizawa K., Saitou K., Suzuki G., Tarumi T., Nakahara H.et al. Effect of mometasone furoate by topical application on allergic rhinitis model in rats. Pharmacology. 61:2000;91-95.
18. Minshall E., Ghaffar O., Cameron L., O'brien F., Quinn H., Rowe-Jones J.et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 118:1998;648-654.
19. Ciprandi G., Tosca M.A., Passalacqua G., Canonica G.W. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Ann. Allergy Asthma Immunol. 86:2001;433-438.
20. Chapman R.W., Sehring S.J., Garlisi C.G., Falcone A., Kung T.T., Stelts D.et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittel-Forschung., Drug Res. 48:1998;384-391.
21. Inman M.D., Watson R.M., Rerecich T., Gauvreau G.M., Lutsky B.N., Stryszak P.et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am. J. Respir. Crit. Care Med. 164:2001;569-574.
22. Cypcar D., Sorkness R., Sedgwick J., Nagata M., Clough J., Kaplan M.et al. Rat eosinophils: isolation and characterization of superoxide production. J. Leukoc. Biol. 60:1996;101-105.
23. Alves A.C., Pires A.L.A., Cruz H.N., Serra M.F., Diaz B.L., Cordeiro R.S.B.et al. Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. Eur. J. Pharmacol. 312:1996;89-96.
24. Gärtner I. Separation of human eosinophils in density gradients of polyvinylpyrrolidone-coated silica gel (Percoll). Immunology. 40:1980;133-136.
25. Sedgwick J.B., Vrtis R.F., Gourley M.F., Busse W.W. Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils. J. Allergy Clin. Immunol. 81:1988;876-883.
26. 1-antihistaminic compound levocabastine. Arzneimittel-Forschung., Drug Res. 43:1993;1331-1337.
27. Tsurufuji S., Sugio K., Takemasa F. The role of glucocorticoid receptor and gene expression in the anti-inflammatory action of dexamethasone. Nature. 280:1979;408-410.
28. Hallam C., Pritchard D.I., Trigg S., Eady R.P. Rat eosinophil-mediated antibody-dependent cellular cytotoxicity: investigations of the mechanisms of target cell lysis and inhibition by glucocorticoids. Clin. Exp. Immunol. 48:1982;641-648.
29. Church M.K., Miller P. Time courses of the anti-anaphylactic and anti-inflammatory effects of dexamethasone in the rat and mouse. Br. J. Pharmacol. 62:1978;481-486.
30. Zhang X., Moilanen E., Adcock I.M., Lindsay M.A., Kankaanranta H. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 71:2002;1523-1534.
31. Meagher L.C., Cousin J.M., Seckl J.R., Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 156:1996;4422-4428.
32. Evans P.M., Barnes P.J., Chung K.F. Inhibition of human eosinophil superoxide anion production by dexamethasone. Br. J. Pharmacol. 100:1990;446P.
33. Ezeamuzie C.I., Al-Hage M. Effects of some anti-asthma drugs on human eosinophil superoxide anions release and degranulation. Int. Arch. Allergy Immunol. 115:1998;162-168.
34. Clark R.A.F., Gallin J.I., Fauci A.S. Effects of in vivo prednisone on in vitro eosinophil and neutrophil adherence and chemotaxis. Blood. 53:1979;633-641.
35. Altman L.C., Hill J.S., Hairfield W.M., Mullarkey M.F. Effects of corticosteroids on eosinophil chemotaxis and adherence. J. Clin. Invest. 67:1981;28-36.
36. Shindo K., Koide K., Fukumura M. PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro. Biochem. Biophys. Res. Commun. 237:1997;146-151.
37. Miyamasu M., Misaki Y., Izumi S., Takaishi T., Morita Y., Nakamura H.et al. Glucocorticoids inhibit chemokine generation by human eosinophils. J. Allergy Clin. Immunol. 101:1998;75-83.
38. Nagase H., Miyamasu M., Yamaguchi M., Kawasaki H., Ohta K., Yamamoto K.et al. Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils. J. Allergy Clin. Immunol. 106:2000;1132-1139.
39. Lim L.H.K., Flower R.J., Perretti M., Das A.M. Glucocorticoid receptor activation reduces CD11b and CD49d levels on murine eosinophils. Characterization and functional relevance. Am. J. Respir. Cell Mol. Biol. 22:2000;693-701.
40. Harrington P.M., Newton D.J., Williams C.M.M., Hunt J.A., Dearman R.J., Kimber I.et al. Eotaxin and eotaxin receptor (CCR3) expression in Sephadex particle-induced rat lung inflammation. Int. J. Exp. Pathol. 80:1999;177-185.
41. Croxtall J.D., Choudhury Q., Flower R.J. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br. J. Pharmacol. 130:2000;289-298.
42. Kurihara K., Wardlaw A.J., Moqbel R., Kay A.B. Inhibition of platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils and neutrophils by the specific ginkgolide-derived PAF antagonist, BN 52021. J. Allergy Clin. Immunol. 83:1989;83-90.
43. Okubo Y., Tsukadaira A., Takashi S., Kubo K., Koyama S. Chemotaxis of human CD4+ eosinophils. Int. Arch. Allergy Immunol. 125(Suppl. 1):2001;19-21.
44. Smith C.L., Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittel-Forschung., Drug Res. 48:1998;956-960.
45. Hagan J.B., Kita H., Gleich G.J. Inhibition of interleukin-5 mediated eosinophil viability by fluticasone 17-propionate: comparison with other glucocorticoids. Clin. Exp. Allergy. 28:1998;999-1006.
46. Stellato C., Atsuta J., Bickel C.A., Schleimer R.P. An in vitro comparison of commonly used topical glucocorticoid preparations. J. Allergy Clin. Immunol. 104:1999;623-629.